Prevalence and incidence of systemic lupus erythematosus in France: A 2010 nation-wide population-based study

Arnaud, Laurent; Fagot, Jean-Paul; Mathian, Alexis; Païta, Michel; Fagot-Campagna, A.; Amoura, Zahir

doi:10.1016/j.autrev.2014.08.034

Cited by 123 publications

(88 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Data from the French SHI find overall incidence rates of 0.9 and 5.5 per 100 000 person-years in men and women 11. While the overall incidence rates of men agree, the overall rate of German women is less than half of the French rate.…”

Section: Discussionmentioning

confidence: 89%

“…Data from the French SHI find overall incidence rates of 0.9 and 5.5 per 100 000 person-years in men and women. 11 While the overall incidence rates of men agree, the overall rate of German women is less than half of the French rate. While part of this difference may be explained by a higher incidence rate in the French overseas territories, 11 the German rate for women still appears to be low.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Age-specific and sex-specific incidence of systemic lupus erythematosus: an estimate from cross-sectional claims data of 2.3 million people in the German statutory health insurance 2002

et al. 2016

View full text Add to dashboard Cite

ObjectiveTo provide an estimate of age-specific incidence rate of physician-diagnosed systemic lupus erythematosus (SLE) for German men and women.MethodsThe age-specific and sex-specific prevalence of diagnosed SLE in claims data is used to estimate the incidence in the German male and female population. The claims data set stems from a representative sample of the statutory health insurance in 2002 and comprises 2.3 million people. The statutory health insurance covers >85% of the German population.ResultsThe estimated incidence rates are 0.9 (95% CI 0.7 to 1.1) per 100 000 person-years for men and 1.9 (95% CI 1.7 to 2.2) per 100 000 person-years for women. The age-specific incidence rate of SLE in the male population has a maximum of 2.2 (95% CI 1.0 to 3.4) per 100 000 person-years at the age of 65–70 years. In women, the incidence is peaking at the rate of 3.6 (95% CI 2.9 to 4.3) cases per 100 000 person-years at the age of 20–25 years, but has a second local maximum (2.6, 95% CI 1.5 to 3.8) at menopausal age.ConclusionsFor the first time, representative data on the incidence of SLE in Germany are provided. The estimated incidence rates of SLE for men and women in Germany are at the lower end of other estimates from comparable European countries.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Age-specific and sex-specific incidence of systemic lupus erythematosus: an estimate from cross-sectional claims data of 2.3 million people in the German statutory health insurance 2002

et al. 2016

View full text Add to dashboard Cite

show abstract

“…A recent UK retrospective cohort study also confirmed the highest incidence and prevalence of SLE in people with black Caribbean ethnicity and a higher prevalence in Asian compared to white patients [9]. Similarly, in a large French nationwide study, the prevalence of SLE was also much higher in the Caribbean overseas areas and lowest in the French northwestern metropolitan territories [10]. …”

Section: Ethnicity and Prevalence Of Systemic Lupus Erythematosusmentioning

confidence: 71%

Lupus Nephritis: A Different Disease in European Patients?

Tesař

Hrušková²

2015

Kidney Dis

View full text Add to dashboard Cite

Background: Lupus nephritis (LN) is still associated with significant mortality and substantial risk of progression to end-stage renal failure. Its outcome is related to the class and severity of LN and response to treatment, and it is poorer in patients with renal relapses. Ethnicity has a relatively well-defined impact on the outcome of the patients and their response to treatment and must always be taken into consideration in treatment decisions. Summary: In this article, we provide a review of the impact of ethnicity on the prevalence of systemic lupus erythematosus (SLE), the proportion of patients with SLE developing LN, outcomes of SLE and LN and response of LN to treatment. In European patients, the prevalence of SLE and the proportion of SLE patients with LN are lower and the outcome of LN is better than in nonwhite populations. European patients may respond better to some modes of treatment [e.g. cyclophosphamide (CYC) or rituximab] and may be less frequently refractory to treatment compared to black patients with LN. Although these differences may be largely genetically driven, socioeconomic factors (poverty, education, insurance, access to health care and adherence to treatment) may also play a significant role in some disadvantaged patients. Key Message: Treatment of LN may be different in patients with different ethnicity. Less aggressive disease in European patients may better respond to less aggressive treatment. Treatment of LN in nonwhite patients may require newer (more effective) therapeutic approaches, but targeting negative socioeconomic factors might be even more effective. Facts from East and West: (1) The prevalence of SLE is lower among Caucasians than other ethnicities. A higher prevalence is observed among Asians and African Americans, while the highest prevalence is found in Caribbean people. The prevalence of LN in Asian SLE patients is much higher than in Caucasians as well. However, the 10-year renal outcome and renal survival rate appear to be better in Asians. (2) Polymorphisms of genes involved in the immune response, such as Fcγ receptor, integrin alpha M, TNF superfamily 4, myotubularin-related protein 3 and many others, might be partly responsible for the differences in prevalence between the different ethnic groups. European ancestry was shown to be associated with a decrease in the risk of LN even after adjustment for genes most associated with renal disease. (3) Access to health care is a key determinant of disease progression, treatment outcome and the management of complications such as infections, particularly in South Asia, and might also explain disparities between clinical outcomes. (4) The efficacy of low-dose CYC combined with corticosteroids for induction treatment of LN was proved in European Caucasian patients. This treatment is also used in Asia, although no formal evaluation of efficacy and safety in comparison with other treatment regimens exists in this population. The efficacy of mycophenolate mofetil (MMF) is similar to that of CYC, and similar between Asi...

show abstract

“…pSLE is associated with an increased risk for severe clinical course and major organ damage in comparison to adults. However, because of the low prevalence of pSLE [2], causes of death are underreported in the pediatric population. In France, a previous retrospective multicenter survey conducted on a ten-year period ( Table 1) identified only 12 deaths in pSLE patients [3].…”

mentioning

confidence: 98%

Acute pancreatitis as a cause of mortality in pediatric systemic lupus erythematosus: Results of a multiple cause-of-death analysis in France

Chiche

Jourde-Chiche

Bader-Meunier

et al. 2016

Seminars in Arthritis and Rheumatism

View full text Add to dashboard Cite

Prevalence and incidence of systemic lupus erythematosus in France: A 2010 nation-wide population-based study

Cited by 123 publications

References 29 publications

Age-specific and sex-specific incidence of systemic lupus erythematosus: an estimate from cross-sectional claims data of 2.3 million people in the German statutory health insurance 2002

Age-specific and sex-specific incidence of systemic lupus erythematosus: an estimate from cross-sectional claims data of 2.3 million people in the German statutory health insurance 2002

Lupus Nephritis: A Different Disease in European Patients?

Acute pancreatitis as a cause of mortality in pediatric systemic lupus erythematosus: Results of a multiple cause-of-death analysis in France

Contact Info

Product

Resources

About